Fluciclovine PET/CT for Prostate Cancer

Fluciclovine (Axumin) PET/CT for Prostate Cancer: Applications
ACNM/SNMMI Joint Webinar

Gary Ulaner, MD, PhD, FACNM; Katherine Zukotynski, BASc, MD, PhD, P.Eng; Twyla Bartel, DO, MBA, FACNM, FSNMMI 

Ashwin Parihar, MBBS, MD       

Jonathan McConathy, MD, PhD

University of Alabama

Course Summary
Fluciclovine (Axumin) PET has been FDA approved for patients with prostate cancer.  This webinar will review the clinical applications and interpretation of Fluciclovine PET.  The target audience will be  nuclear medicine physicians and radiologists.  The course would provide expertise in the proper application and interpretation of Fluciclovine PET for webinar attendees.  The expected outcomes are that attendees will better understand Fluciclovine PET and will be able to apply it more appropriately and effectively in their clinics.

Course Objectives
1. Discuss the basic mechanism of Fluciclovine PET

2. Discuss appropriate clinical indications for Fluciclovine PET

3. Improve interpretation of Fluciclovine PET

CE Information
CE Credit applications for physicians, pharmacists, physicists and technologists are pending. Check back for updates regarding CE Credit status.

3/15/2022 12:00 PM - 1:00 PM

Register for Another Webinar

Sign In to Register